poisar

Stock

Beam Therapeutics Inc. BEAM

$26.31-4.45%

Overview

BEAM market data

Price History

BEAM price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.81
Diluted earnings per share over the trailing twelve months.
Beta
2.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$15.60 – $38.26
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.7K · P/B 2.27 · P/S 16.57.

Company news

10 captured
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026Benzinga · Jul 23, 2026, 11:02 AM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?The Motley Fool · Jul 20, 2026, 6:15 PM
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics CaseBenzinga · Jul 8, 2026, 5:35 PM
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price TargetBenzinga · Jul 8, 2026, 5:30 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)Benzinga · Jun 29, 2026, 2:40 PM
The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For PhenylketonuriaBenzinga · Jun 18, 2026, 11:15 AM
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceGlobenewswire Inc · May 18, 2026, 8:15 PM
Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FLBenzinga · May 18, 2026, 8:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock